Manon M.J. Cox, PhD, MBA
Dr. Manon Cox founded NextWaveBio in early 2018 initially providing scientific and strategic direction to various biopharmaceutical companies. Prior to that she led the development of Flublok®, the only FDA approved recombinant influenza vaccine at Protein Sciences Corporation where she served as President and Chief Executive Officer since April 2010 and Director since 2008. She joined Protein Sciences in 1998 as Director of Business Development and became Chief Operating Officer in 2003.
She serves on the Board of Directors of Vaxxas, the Netherland-America Foundation including its Education Committee, the International Society of Vaccines, and various Scientific Advisory Boards in the vaccine development space.
Stanley A Plotkin, MD
Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania. He was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. For seven years, he was the Medical and Scientific Director of Sanofi Pasteur, based at Marnes-la-Coquette, outside Paris. He is now a consultant to vaccine developers and non-profit research organizations.
His bibliography includes over 800 articles and he has edited several books including a textbook on vaccines. Dr. Plotkin developed the rubella vaccine now in standard use throughout the world, is co-developer of the pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.
Michel De Wilde, PhD
Dr. Michel De Wilde was the Senior Vice President of Research & Development at Sanofi Pasteur, the human vaccines division of Sanofi from 2001 until June 2013. In this position, he was responsible for managing approximately 1,500 employees and a broad portfolio of approximately 20 development projects. Prior to Sanofi, Michel held positions of increasing responsibility at GSK vaccine division. He led the development of EngerixB and was a co-inventor of RTS/S, the first ever Malaria vaccine. Currently, he is the owner of MDWConsultant, LLC.
Dr. De Wilde is or has been a member of a number of Scientific Advisory Boards, including CEPI, COVAX Independent Product Group and other COVID-related advisory bodies. Dr. De Wilde authored over 50 publications during the early part of his career. He also serves on the Board of VBI Vaccines.
Zak Huang, MD
Dr. Zak Huang was Vice President, Regulatory Affairs, at Nimbus Therapeutics as his most recent past position. He has devoted 30 plus years to the development of new pharmaceutical, biologics, and medical device products.
In the early years, he designed and conducted clinical development programs at Boston Scientific and Eli Lily & Co. His regulatory leadership accomplishments included successful navigation through US, EU, Japan and China regulatory landscape at Merck & Co., CSL Behring, Nimbus Therapeutics, and Boston Scientific, filings and approvals/clearance of numerous clinical and marketing applications, preparation and conduct of a US FDA Advisory Committee meeting, and leading a global regulatory affairs organization.
Amy Zeng, PhD
Dr. Amy Z. Zeng became the 6th Dean of the Sawyer Business School at Suffolk University in late July of 2020. She has over twenty years of experience in higher education and is an accomplished and established scholar in the fields of supply chain management and global logistics. Her research expertise lies in the areas of supply chain risk management and tactics, reverse and sustainable supply chain analysis and design, and global logistics process improvement. She has published over 100 articles, garnered over 3,000 Google scholar citations, received $1M grants to support her research and teaching projects, and delivered more than 110 speeches spanning a wide range of locations and occasions.
